#Italianpharma
LightNews LightNews
pharmaphorum.bsky.social
#Italianpharma group #Chiesi has bolstered its #raredisease business with an agreement to buy #USbiopharma #KalVistaPharma and #Ekterly, the first oral drug for treating exacerbations of the rare disease #hereditaryangioedema (HAE).

pharmaphorum.com/news/chiesi-...
Chiesi signs $1.9bn deal to buy KalVista and its HAE drug
Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
pharmaphorum.com
April 30, 2026 at 10:38 AM
pharmaphorum.bsky.social
#Italianpharma group #Chiesi has named #DavidKhougazian as its new permanent #chiefexecutive, following the departure of Giuseppe Accogli earlier this year to join private equity firm Archimed.

pharmaphorum.com/news/chiesi-...
Chiesi fills permanent CEO role with Flagship's Khougazian
Chiesi has named Flagship's David Khougazian as its new permanent chief executive, following the departure of Giuseppe Accogli earlier this year.
pharmaphorum.com
September 15, 2026 at 12:25 PM
pharmaphorum.bsky.social
The offer on the table for #Italianpharma group #Recordati by #privateequity firms #CVC and #GBL undervalues the company and is unfair to minority #shareholders, according to #hedgefund #Palliser, which is leading a pushback against the deal.

pharmaphorum.com/news/resista...
Resistance grows to Recordati's private equity takeover
The offer for Recordati by private equity firms CVC and GBL undervalues the company and is unfair to minority shareholders, claims activist investor.
pharmaphorum.com
September 14, 2026 at 10:14 AM